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Abstract
Chloroquine was a cheap, extremely effective drug against Plasmodium falciparum until resistance arose. One approach to
reversing resistance is the inhibition of chloroquine efflux from its site of action, the parasite digestive vacuole. Chloroquine
accumulation studies have traditionally relied on radiolabelled chloroquine, which poses several challenges. There is a need
for development of a safe and biologically relevant substitute. We report here a commercially-available green fluorescent
chloroquine-BODIPY conjugate, LynxTag-CQGREEN, as a proxy for chloroquine accumulation. This compound localized to the
digestive vacuole of the parasite as observed under confocal microscopy, and inhibited growth of chloroquine-sensitive
strain 3D7 more extensively than in the resistant strains 7G8 and K1. Microplate reader measurements indicated suppression
of LynxTag-CQGREEN efflux after pretreatment of parasites with known reversal agents. Microsomes carrying either sensitive-
or resistant-type PfCRT were assayed for uptake; resistant-type PfCRT exhibited increased accumulation of LynxTag-CQGREEN,
which was suppressed by pretreatment with known chemosensitizers. Eight laboratory strains and twelve clinical isolates
were sequenced for PfCRT and Pgh1 haplotypes previously reported to contribute to drug resistance, and pfmdr1 copy
number and chloroquine IC50s were determined. These data were compared with LynxTag-CQGREEN uptake/fluorescence by
multiple linear regression to identify genetic correlates of uptake. Uptake of the compound correlated with the logIC50 of
chloroquine and, more weakly, a mutation in Pgh1, F1226Y.
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Introduction
Despite years of intense global effort to eradicate it, malaria is
still one of the deadliest infectious diseases, killing more than 600
000 people in 2010 alone [1,2]. The severest form of malaria is
caused by the protozoan parasite Plasmodium falciparum.
Chloroquine (CQ), once a spectacularly successful antimalarial
drug, was first discovered by the German chemist Johann
Andersag but was mistakenly thought to be too toxic for
therapeutic purposes, an incident which became known as ‘‘the
resochin error’’ (resochin being the name given to the compound
by Andersag) [3,4]. CQ was so effective that it inspired optimism
for the eradication of malaria. However, resistance soon arose, first
appearing along the Thai-Cambodian border in the 1950s. By the
1970s, CQ resistance had spread throughout the world [5,6]. This
resistance is generally attributed to mutations in the pfcrt (P.
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falciparum chloroquine resistance transporter) gene, which codes
for a transporter situated on the membrane of the parasite
digestive vacuole (DV).
During parasite development in the intraerythrocytic cycle,
haemoglobin is digested in the DV and the toxic heme moiety is
released, which the parasite crystalizes into non-toxic hemozoin
[7]. CQ is generally thought to kill the parasite by inhibiting the
formation of hemozoin and thus preventing the detoxification of
free heme [8–10]. In wild-type parasites CQ diffuses through the
DV membrane and is diprotonated in the acidic environment of
the DV, acquiring a net positive charge which prevents it from
escaping the DV; however, mutant PfCRT found in CQ-resistant
parasites effluxes this charged CQ out of the DV, removing it from
its site of action [11]. Although the current first line artemisinin-
combination therapies are effective in clearing parasitaemia,
resistance against artemisinins has emerged [12–17]. There is
therefore an urgent need to develop novel antimalarial strategies.
Several research groups, including our own, have tried different
approaches to tackle the problem of CQ resistance by either
reversing CQ resistance with a PfCRT inhibitor or synthesizing
‘‘reversed’’ CQ analogues that cannot be effluxed by PfCRT [18–
24]. The ultimate goal is to reintroduce CQ as a viable treatment
for malaria. Both development of PfCRT inhibitors and synthesis
of ‘‘reversed’’ CQ analogues require a sensitive assay for CQ
uptake which is typically performed by the use of radiolabelled CQ
[22,25–28]. Such methods are difficult to adopt in a high-
throughput screen and may raise concerns of safety. To overcome
this technical difficulty, fluorescent derivatives of chloroquine have
recently been developed and used for this purpose; fluorophores
used include 6-(N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl)amino)hex-
anoic acid (NBD) [29], coumarin [21,30], and 4, 4-difluoro-4-
bora-3a, 4a-diaza-s-indacene (BODIPY) [31].
BODIPY derivatives typically exhibit strong fluorescence and
are relatively inert in biological conditions [32]. Furthermore, their
maximum emission wavelengths are in the green-red region [32],
allowing them to be used with many DNA dyes that fluoresce blue,
such as the DAPI and Hoechst stains. These properties make
BODIPY a promising candidate as a marker for CQ uptake in P.
falciparum. We therefore present here the characterization of a
commercially-available BODIPY-CQ conjugate, LynxTag-
CQGREEN, in several laboratory strains and clinical isolates.
Methods
Parasite culture and synchronization
P. falciparum laboratory strains 3D7 (MRA-102), K1 (MRA-
159), 7G8 (MRA-154), HB3 (MRA-155), CS2 (MRA-96), T9-94
(MRA-153), and Dd2 (MRA-156) were obtained from MR4,
ATCC Manassas Virginia. Strain T9/96 was obtained from The
European Malaria Reagent Repository. A further twelve clinical
isolates were collected from the Mae Sot district, Tak Province, in
northwest Thailand at the Shoklo Malaria Research Unit; these
isolates are prefixed ‘SMRU’. Parasites were continuously cultured
in complete malaria culture media (MCM) consisting of RPMI
1640 (Life Technologies) supplemented with 0.5% (w/v) Albumax
I (Invitrogen), 0.005% (w/v) hypoxanthine, 0.03% (w/v) L-
glutamate, 0.25% (w/v) gentamycin, with human erythrocytes at
2.5% haematocrit. Cultures were gassed with a mixture of 3%
CO2, 4% O2 and 93% N2 and incubated at 37uC. Synchroniza-
tion of parasite cultures was performed by resuspending erythro-
cytes in 5% (w/v) D-sorbitol and incubating at 37uC for 10 min,
after which the erythrocytes were washed twice, resuspended in
MCM and returned to culture conditions. Thin Giemsa smears
were made before each experiment to determine parasitemia and
parasite stage.
Compound preparation
For work involving parasites, chlorpheniramine maleate salt,
chlorpromazine hydrochloride, desipramine hydrochloride, pro-
methazine hydrochloride, verapamil hydrochloride and CQ
diphosphate (all from Sigma-Aldrich) were dissolved in PBS to a
working concentration of 1 mM. LynxTag-CQGREEN (BioLynx
Technologies, Singapore; hereafter abbreviated to ‘CQGREEN’)
was dissolved in DMSO to the same concentration. All
compounds were stored at 220uC and protected from light. For
microsome uptake assays, methiothepin mesylate salt, metergoline,
loperamide hydrochloride, octoclothepin maleate salt, mibefradil
dihydrochloride hydrate, L703,606 oxalate salt hydrate, and
chlorprothixene hydrochloride (all from Sigma-Aldrich) were
dissolved in DMSO to 10 mM and stored at 4uC. Verapamil
hydrochloride, adenosine triphosphate (ATP), and CQ diphos-
phate (all from Sigma-Aldrich) were dissolved in water to 7.5 mM,
50 mM and 0.1 M respectively and stored at 220uC. Tritiated
CQ (3H-CQ; from Moravek Biochemicals and Radiochemicals)
was diluted in water to 5.32 mM and stored at 220uC; specific
activity was 4.7 Ci/mmol.
Reinvasion half-maximal inhibitory concentration (IC50)
Synchronized ring-stage cultures at 1–2% parasitemia, 1.25%
haematocrit were incubated with either CQ or CQGREEN at a
range of concentrations for 48 h in 96-well flat-bottomed plates at
culture conditions. Following this, cells were stained with 1 mg/ml
of Hoechst 33342 (Invitrogen) for 30 min at 37uC, washed twice
and resuspended in PBS. Parasitemia was then assessed with the
CyAn ADP flow cytometer (Beckman Coulter). IC50s were
determined by plotting the measurements in Graphpad Prism 5
using a variable slope logistic curve.
Confocal imaging
200 ml cultures of 3D7 at 3% parasitemia, 1.25% haematocrit
were incubated with CQGREEN for 2 h at 2 mM in a 96-well plate
format. Erythrocytes were then washed twice and stained with
Hoechst 33342 as previously. Wet mounts of stained parasites
were visualized under 6100 magnification with the Fluoview
FV1000 confocal microscope (Olympus). Hoechst and CQGREEN
were excited at 405 nm and 488 nm with emissions captured at
430–470 nm and 505–525 nm respectively.
Parasite CQGREEN uptake assay
Synchronized trophozoite-stage cultures at 3–5% parasitemia
were resuspended in 200 ml of MCM with 2 mM of CQGREEN to
2.5% haematocrit in a 96-well plate format. The parasites were
then incubated for 2 h at culture conditions, after which they were
washed twice and resuspended in PBS. Cells were allowed to settle
in a Nunc F96 MicroWell black non-treated polystyrene plate
(Thermo Scientific) for 1 h. Fluorescence was then measured with
the Infinite M200 microplate reader (Tecan) with excitation and
emission wavelengths of 488 nm and 520 nm respectively. K1
chemoreversal assays were performed by pretreatment with
10 mM of the reversal agents for 30 min prior to the addition of
CQGREEN.
Preparation of microsomes carrying PfCRT
PfCRT originating from P. falciparum strains Dd2 or 3D7 were
expressed in Pichia pastoris KM71 and microsomes harvested as
described previously [33]. Microsomal levels of PfCRT were
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determined by western blot with standard curves generated from
blots of purified PfCRT.
Uptake kinetics in microsomes
In order to assess the Michaelis-Menten kinetics of CQGREEN
uptake by the microsomes, total or non-specific uptake was
measured. Non-specific uptake was determined by pretreating
microsomes with unlabelled CQ at 1000 times of the concentra-
tion of CQGREEN used, for 15 min at 37uC, before adding
CQGREEN; total uptake was determined without the pretreatment.
Reactions were carried out in accumulation buffer (0.25 M
sucrose, 10 mM Tris–HCl, 5 mM MgCl2, and 3 mM ATP,
pH 7.5). Following this, microsomes were washed twice in
accumulation buffer, then lysed in lysis buffer (0.75 M HCl, 1%
Triton X-100, 77.5% isopropanol) on ice for at least one hour.
Unlabelled CQ was excluded from the washing step as the
addition of CQ was observed to cause displacement of CQGREEN
from the microsomes, possibly due to the higher affinity of CQ for
PfCRT. Measurement of the fluorescence intensity was performed
using the FLUOstar Galaxy microplate reader (BMG Labtech)
with excitation and emission wavelengths of 480 nm and 520 nm
respectively. For each experiment, measurements were made in
triplicate and the mean calculated. Specific uptake was then
calculated by subtracting non-specific uptake from total uptake.
Non-linear regression analysis with the Michaelis-Menten model
(GraphPad Prism 5) was then applied to obtain the Vmax and Km
of specific uptake.
CQGREEN uptake in PfCRT microsomes
Unless stated otherwise, microsomes were incubated with
15 mM CQGREEN at 37uC for 15 min. For uptake inhibition
assays, microsomes were pre-incubated with chemoreversal
compounds [21] for 15 min at 37uC prior to the addition of
CQGREEN. All data presented are specific uptake based on the
calculations stated above.
3H-CQ uptake in PfCRT microsomes
3H-CQ uptake was measured as described previously [33], with
some modifications. Non-specific uptake was determined by pre-
incubation with 200-fold unlabelled CQ. Incubation was per-
formed with 3H-CQ at 308 nM for 5 min, after which 200-fold
unlabelled CQ was added to stop the reaction. Microsomes were
then precipitated by the addition of polyethylene glycol (PEG)
8000 and washed twice with accumulation buffer containing 200-
fold unlabelled CQ to remove excess 3H-CQ. Microsomes were
then resuspended in scintillation buffer and agitated overnight.
Radioactivity was measured using the LS 5600 Scintillation
Counter (Beckman). All data presented are specific uptake.
Genotyping of strains and isolates
To assess pfmdr1 polymorphisms, parasite DNA from in vitro
cultures was extracted with the QIAamp DNA Mini kit (Qiagen)
as per the manufacturer’s instructions. For pfcrt polymorphisms,
total RNA was extracted with the RNeasy Mini Kit (Qiagen) and
reverse transcription performed with SuperScript III (Invitrogen)
as per manufacturers’ instructions. Polymerase chain reaction
(PCR) mixtures were made with 200 mM of each dNTP, 0.5 mM
forward primer, 0.5 mM reverse primer, 0.02 U/ml Phusion DNA
polymerase (Thermo Scientific), 6 ml of 56 Phusion HF buffer,
and 1 ml of genomic DNA or cDNA to a total reaction volume of
30 ml. Thermocycler parameters were as follows: 98uC for 30 s,
followed by 35 cycles of 98uC for 10 s, 60uC for 30 s, and 72uC for
1 min. Primers used for pfmdr1 sequencing were 59- ATGGG-
TAAAGAGCAGAAAGA and 59- TCCACAATAACTTGCAA-
CAGT, or 59- GTCAAGCGGAGTTTTTGC and 59- TAT-
TCTCTGTTTTTGTCCAC. Pfcrt-specific primers were 59-
GACGAGCGTTATAGAGAAT and 59- CTTCGGAATCTT-
CATTTTCT. PCR products were purified with the QIAquick
PCR purification kit as per manufacturer’s instructions. Purified
PCR products were sequenced by a commercial vendor (AIT
Biotech, Singapore). Copy number of pfmdr1 was assessed by real-
time PCR as previously reported [34]. Briefly, reaction mixtures
were prepared with TaqMan universal PCR master mix (Applied
Biosystems), 5.5 mM MgCl2, 300 nM dNTPs, 300 nM each of
forward and reverse primers, and 100 nM of the probe.
Thermocycler parameters were 95uC for 10 min, then 40 cycles
of 95uC for 15 s and 60uC for 1 min. Forward and reverse primers
used were 59- TGCATCTATAAAACGATCAGACAAA and 59-
TCGTGTGTTCCATGTGACTGT respectively, and TaqMan
probe was 59- 6FAM-TTTAATAACCCTGATCGAAATG-
GAACCTTTG-TAMRA. A reference gene, b-tubulin, was also
included; primers were 59- TGATGTGCGCAAGTGATCC and
59- TCCTTTGTGGACATTCTTCCTC, while the probe was
59- VIC-TAGCACATGCCGTTAAATATCTTCCATGTCT-
TAMRA. The threshold cycle (Ct) was analysed by the
comparative Ct method, based on DNA amplification efficiencies
of the pfmdr1 and b-tubulin genes. Pfmdr1 copy number was
calculated according to the following formula: DCt = CtR - CtG,
where CtR is the reference b-tubulin Ct, and CtG is that of
pfmdr1. Each TaqMan run included three reference DNA
samples from clones 3D7, K1, and Dd2 having pfmdr1 copy
numbers of 1, 1, and 3 respectively.
Statistical analyses
All statistical analyses were performed with SPSS 21. Chemor-
eversal assays were assessed with Student’s t test, 2-tailed. Multiple
linear regression was performed with the stepwise method, using
the log of IC50s and with dummy coded values for the respective
amino acid residues.
Ethics statement
The blood collection protocol for in vitro malaria culture was
approved by the Institutional Review Board (NUS-IRB Reference
Code: 11–383, Approval Number: NUS-1475) of the National
University of Singapore (NUS). All participants provided written
informed consent. The clinical isolates used were obtained under
ethical guidelines in the approved protocol: OXTREC Reference
Number 29–09 (Center for Clinical Vaccinology and Tropical
Figure 1. CQGREEN localization in P. falciparum 3D7. Parasites were
stained with CQGREEN and Hoechst and visualized via confocal
microscopy under a 1006 objective. CQGREEN accumulates in the DV
but also slightly stains parasite cytosol; erythrocyte cytosol is not
stained. Arrowheads denote the DV. Scale bars represent 5 mm.
doi:10.1371/journal.pone.0110800.g001
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Medicine, University of Oxford, Oxford, United Kingdom). Use
of field isolates in NUS was in accordance with NUS IRB
(Reference Code: 12–369E).
Results and Discussion
Validation of CQGREEN localization and antimalarial
activity
CQ is generally believed to accumulate in the DV as a result of
ion-trapping [35,36]. Confocal microscopy was therefore per-
formed to ascertain the localization of CQGREEN in the parasite.
Cultures of P. falciparum 3D7 were co-stained with Hoechst dye
and CQGREEN, revealing a preferential accumulation of
CQGREEN in the parasite DV (Fig. 1). Interestingly, CQGREEN
fluorescence was also observed in the parasite cytosol but not in
the erythrocyte cytosol. As CQGREEN is a CQ analog, the
antimalarial potency of CQGREEN should be similar to that of CQ.
To assess this, reinvasion IC50s of CQ and CQGREEN on the
laboratory strains 3D7, 7G8 and K1 were determined. CQGREEN
showed the same general trend of antimalarial activity as CQ, in
that it is most potent against 3D7, followed by 7G8, then K1
(Fig. 2A, 2B).
CQGREEN fluorescence as a proxy for CQ uptake in
parasites
Next, we determined if CQGREEN uptake by the highly CQ-
resistant strain K1 can be increased by pre-treatment with
chemosensitizers. Verapamil, chlorpromazine, chlorpheniramine,
desipramine, and promethazine have previously been reported to
reverse CQ resistance and increase CQ uptake in CQ-resistant
Figure 3. CQGREEN uptake by Dd2 PfCRT microsomes. Total
uptake of CQGREEN was measured at various CQGREEN concentrations in
microsomes carrying Dd2 PfCRT. Non-specific uptake of CQGREEN was
measured with pre-treatment of excess unlabelled CQ. Specific uptake
was estimated as the difference between total and non-specific uptake.
Vmax and Km of the specific uptake was 938.5 nmol/mg PfCRT/min and
105.1 mM respectively. Data are means 6 S.E.M.; n$3.
doi:10.1371/journal.pone.0110800.g003
Figure 2. Validation of CQGREEN activity and uptake in laboratory strains. (A, B) CQGREEN IC50s recapitulates CQ IC50s in three P. falciparum
laboratory strains, 3D7, 7G8 and K1. 3D7 is a CQ-susceptible strain, 7G8 is moderately resistant, while K1 is highly CQ-resistant. Data shown are
geometric means from at least 3 experiments. As the error from IC50s are not symmetrical, error bars indicate 95% confidence intervals instead of the
standard error of the mean (S.E.M.). (C) CQGREEN uptake as measured by fluorescence is increased in CQ-resistant K1 when pretreated with
chemoreversal agents. 3D7 exhibits highest uptake of CQGREEN. Data are means from at least 3 experiments; error bars are S.E.M. Veh: vehicle control;
VPM: verapamil; CPZ: chlorpromazine; CPN: chlorpheniramine; DSP: desipramine; PMZ: promethazine. *: p,0.05.
doi:10.1371/journal.pone.0110800.g002
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strains [37–41]. CQ-sensitive 3D7 was included as a reference for
complete reversal. All reversal agents except desipramine induced
a significant increase in CQGREEN fluorescence (Fig. 2C). Desi-
pramine is in fact a less potent reversal agent compared to
verapamil when tested in the resistant strain Dd2, and two CQ-
resistant field isolates [42]; this may explain why desipramine’s
effect on CQGREEN uptake did not achieve statistical significance.
Taken together with the CQGREEN IC50 data, we believe that the
reversibility of CQGREEN uptake by known chemoreversal agents
suggests that CQGREEN shares similar structural properties with
CQ.
Uptake of CQGREEN in microsomes bearing PfCRT
To test if CQGREEN can be transported by PfCRT, we have
expressed PfCRT in Pichia pastoris and used the microsomes
derived to study CQGREEN uptake. Figure 3 shows that CQGREEN
uptake in Dd2 PfCRT-expressing microsomes is specific. At the
highest concentration of CQGREEN used (200 mM), uptake was
close to saturated. Michaelis-Menten approximation of CQGREEN
uptake kinetics in Dd2 microsomes (Figure 3) yields a Vmax and
Km of 938.5 nmol/mg PfCRT/min and 105.1 mM respectively,
which are approximately 2000 and 500 times higher compared to
when 3H-CQ was used [33]. Conjugation of CQ with the
BODIPY fluorophore may have altered the affinity of PfCRT for
the molecule. However, both the high (micromolar) Km and non-
saturation of CQGREEN transport are consistent with a previous
report in a Xenopus oocyte system using 3H-CQ [43]. We have
also compared CQGREEN uptake in microsomes with PfCRT
originating from either CQ-sensitive 3D7 or CQ-resistant Dd2.
CQGREEN uptake in Dd2 PfCRT-expressing microsome was
96.07 nmol/mg PfCRT/min, which was about three times that of
3D7 PfCRT (31.64 nmol/mg PfCRT/min) (Figure 4). PfCRT-
Figure 4. ATP-dependent, verapamil-sensitive uptake of CQGREEN in microsomes. Yeast microsomes expressing CQ-sensitive or -resistant
PfCRT (‘‘PfCRT-3D7’’ and ‘‘PfCRT-Dd2’’ respectively), or microsomes from plasmid vector control (‘‘No PfCRT’’), were incubated with CQGREEN under
different conditions. Preincubation with 150 mM verapamil abrogated CQGREEN uptake from PfCRT-Dd2 but did not affect uptake in PfCRT-3D7
microsomes. Removal of ATP from buffer abolished CQGREEN uptake entirely. **, ***: p,0.005 and p,0.001 respectively, against untreated control.
###: p,0.001. N.s.: not significant. Data presented are means 6 S.E.M.; n$3.
doi:10.1371/journal.pone.0110800.g004
Figure 5. CQGREEN uptake by resistant-type PfCRT is inhibited by mibefradil in a dose-dependent manner. Microsomes were
preincubated with varying concentrations of the PfCRT inhibitor mibefradil prior to addition of CQGREEN. At the highest concentration of 10 mM,
mibefradil drastically suppressed CQGREEN uptake in PfCRT-Dd2 microsomes but had no significant effect on uptake in PfCRT-3D7 microsomes. *, ***:
p,0.05 and p,0.001 respectively, against no mibefradil control (Ctrl). Data presented are means 6 S.E.M.; n$3.
doi:10.1371/journal.pone.0110800.g005
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mediated transport of CQ is thought to be ATP-dependent
[25,44]. Here we demonstrated that removal of ATP completely
abolished CQGREEN uptake in both Dd2 and 3D7 PfCRT
microsomes (Figure 4). Verapamil, a known CQ resistance
chemosensitizer which has no effect on CQ-sensitive strains, can
reverse CQGREEN uptake in Dd2 PfCRT to almost that of 3D7
level but has almost no effect on 3D7 PfCRT (Figure 4). These
results suggest that CQGREEN is similar to CQ in that (1) it is
differentially recognized by CQ-resistant versus CQ-sensitive
PfCRT, (2) its uptake by PfCRT is ATP-dependent, and (3) its
uptake by CQ-resistant PfCRT is verapamil-reversible. Others
have shown that extensive CQ side-chain modifications can render
the CQ analogues not transportable by PfCRT and abolish their
verapamil sensitivity [45,46]. Our findings show that the
additional BODIPY moiety in CQGREEN still allows CQGREEN
to be differentially recognized by resistant versus sensitive PfCRT
and these transport activities are still sensitive to verapamil. To
demonstrate the usefulness of CQGREEN in screening for PfCRT
inhibitors, we found that CQGREEN uptake by Dd2 PfCRT
microsomes can be inhibited by mibefradil, a novel potent
chemosensitizer [21], in a dose-dependent manner (Figure 5).
Inhibition of CQGREEN uptake by a panel of known chemoreversal
agents was compared to that using 3H-CQ (Figure 6). Mean
uptake of CQGREEN was positively correlated with that of
3H-CQ
(b of 60.24, p= 0.002), showing moderately good agreement
between CQGREEN and
3H-CQ uptake (R2 = 0.766). However,
3H-CQ uptake was roughly 100 times greater than that of
CQGREEN.
Polymorphisms and copy number variation in pfcrt and
pfmdr1
Eight laboratory strains and twelve clinical isolates were
sequenced for polymorphisms in PfCRT and Pgh1, the proteins
encoded by the genes pfcrt and pfmdr1 respectively. Residues
examined were 72, 74, 75, 76, 220, 271, 326, 356, and 371 for
PfCRT, and 86, 184, 1034, 1042, 1226, and 1246 for Pgh1. These
residues were chosen for analysis as they were previously
implicated in modulating multidrug resistance as well as resistance
against CQ [47,48]. Copy number of pfmdr1 was also determined
for each strain and isolate. All clinical isolates showed Dd2-type
PfCRT mutations, whereas Pgh1 mutations and pfmdr1 copy
numbers were more varied (Table 1).
Genetic correlates of CQGREEN uptake
All strains and isolates were assayed for CQGREEN uptake in the
trophozoite stage, and their CQ IC50s determined with the
standard reinvasion assay. For the entire data set, CQGREEN
uptake was inversely correlated to the log of CQ IC50, with an R
2
of 0.53 (Fig. 7A). However, multiple linear regression with
sequencing and copy number data revealed that CQGREEN uptake
was significantly correlated with not only CQ logIC50 but also a
F1226Y substitution in Pgh1 (b of -587.32 and 178.70, p,0.001
and p=0.024 respectively; adjusted R2 of 0.615). None of the
other mutations was significantly correlated with CQGREEN
uptake. Separating the data set to two subpopulations improved
the R2, to 0.72 in the Pgh1 1226F group and 0.676 in the Pgh1
1226Y group (Fig. 7B). It is tempting to conclude that the Pgh1
F1226Y substitution plays a significant causal role in modulating
CQGREEN uptake, given that it is also correlated with resistance to
artemisinin, mefloquine and lumefantrine [48] and Pgh1’s putative
sequestration of cytosol-active drugs in the DV [49]. However, it
must be kept in mind that the F1226Y mutation was only detected
in the clinical isolates, and given the localized collection of these
isolates within a small geographical region, F1226Y is likely to be
strongly correlated with other undiscovered mutations. In fact, the
PfCRT and Pgh1 haplotypes of the F1226Y mutants examined
were identical, apart from SMRU0501 which had an additional
Pgh1 Y184F substitution (Table 1). It is notable that for the
F1226Y mutants, CQGREEN uptake could range as high as that of
the CQ-susceptible strains (Fig. 7B) while still maintaining CQ
resistance. One possible gene modulating CQGREEN uptake could
be pfmrp, which has been proposed to efflux drugs across the
parasite plasma membrane into the parasitophorous vacuolar
lumen [49], which would still contribute to CQGREEN fluorescence
but sequester the drug from its site of action. Knock-out mutants of
this gene exhibit increased susceptibility to CQ, quinine,
artemisinin, piperaquine, and primaquine [50]. Alternative
mechanisms besides efflux of CQ could perhaps also contribute
to CQ resistance, such as decreased susceptibility to CQ-induced
apoptosis-like cell death [51].
Figure 6. Accumulation of CQGREEN and
3H-CQ in PfCRT-Dd2 microsomes. Microsomes were incubated with 10 mM of chemosensitizers
before addition of CQGREEN or
3H-CQ. Ctrl: negative control; Ver: verapamil; Mtp: methiothepin; Mgl: metergoline; Lop: loperamide; Oct: octoclothepin;
Mib: mibefradil; L703: L703,606; Chl: chlorprothixene. *: p,0.05, comparing CQGREEN uptake against control.
`: p,0.05, comparing 3H-CQ uptake
against control. Data presented are means 6 S.E.M.; n$3.
doi:10.1371/journal.pone.0110800.g006
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Conclusions
CQGREEN is a commercially available fluorescent CQ analog
that interacts with the parasite in a similar fashion to CQ.
CQGREEN presents some advantages over traditional radiolabelled
CQ in uptake studies: it is safer to handle as it is not radioactive,
and its fluorescence properties allows it to be monitored by
common fluorescence equipment. Using a defined microsomal
platform, we showed that CQGREEN interacts with PfCRT in a
manner similar to CQ. Its use as a predictor of CQ susceptibility is
enhanced if residue 1226 of Pgh1 is known. Unlike a typical
reinvasion assay which may require 48 h or more, the use of
CQGREEN allows for measurement of CQ susceptibility within
several hours. We believe that CQGREEN could be a valuable tool
in future drug discovery projects or used in the identification of
factors involved in drug resistance.
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